Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)

Trial Profile

Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Flutafuranol F 18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 25 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 24 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 13 Feb 2014 According to ClinicalTrials.gov record, planned number of patients changed from 50 to 120.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top